Dec. 10 Financial Quick Takes: Inscripta, Aurinia, Akeso, Ribo, Hummingbird, ImmunOs, Peregrine
Inscripta raises $125M series D
Inscripta Inc. raised $125 million in a series D round led by existing investor Paladin Capital, bringing the total capital raised by the company to $260 million since 2015. New investors JS Capital Management and Oak HC/FT participated in the round, as did additional undisclosed existing investors. Inscripta will use the funding to expand commercialization and development of its Onyx platform for CRISPR-based engineering of E. coli and yeast genomes.
Aurinia raises $167M follow-on
Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH; TSX:AUP) raised $166.7 million in an upsized follow-on late Monday through the sale of 11.1 million shares at $15, a 3% discount from Friday’s close. The company proposed early Monday to raise $150 million. Aurinia rose 80% on Dec. 5 after reporting that voclosporin met primary and secondary endpoints in the Phase III AURORA study to treat lupus nephritis. Aurinia shares added 12% to $17.70 on Tuesday...